Previous Close | 51.47 |
Open | 51.36 |
Bid | 22.04 x 800 |
Ask | 0.00 x 800 |
Day's Range | 50.90 - 55.83 |
52 Week Range | 49.24 - 115.25 |
Volume | |
Avg. Volume | 462,526 |
Market Cap | 3.767B |
Beta (5Y Monthly) | 1.67 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.32 |
Earnings Date | May 02, 2022 - May 06, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 128.81 |
Oral presentations include longer term durability data from DTX301 and DTX401, and manufacturing data on the Pinnacle PCL™ (AAV vector Producer Cell Line) platform and technologyNOVATO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its investigational gene t
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?